Interleukin-23 in lung and airway diseases: from pathogenesis to precision-guided therapeutic targeting - PubMed
6 hours ago
- #Targeted Therapy
- #Interleukin-23
- #Lung Diseases
- IL-23 is a cytokine from the IL-12 family produced by antigen-presenting cells, central to adaptive immunity by promoting Th17 cell activity.
- In physiological conditions, IL-23 helps maintain pulmonary immune homeostasis and defends against bacterial and fungal pathogens.
- Dysregulated IL-23 signaling leads to chronic inflammation and tissue damage, playing a key role in the severity of various lung diseases.
- IL-23 is associated with increased disease severity, corticosteroid resistance, airway remodeling, and fibrosis in chronic lung conditions.
- The review discusses IL-23's role in chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis, and COVID-19.
- Targeting IL-23 offers therapeutic potential for precision-guided strategies to modulate inflammation and remodeling, aided by biomarkers.